Lyme Disease Treatment Market Research, 2031
The global Lyme disease treatment market was valued at $737.5 million in 2021 and is projected to reach $1.6 billion by 2031, growing at a CAGR of 8.4% from 2022 to 2031. Lyme disease treatment market share is estimated to grow over the forecast period due to the rising incidence of Lyme disease among individuals worldwide. The bite of a black-legged tick transmits Lyme disease to humans. The number of Lyme disease cases is rapidly increasing, which has increased the need for Lyme disease therapy. This feature is projected to enhance the market growth even further. In addition, increased research initiatives to develop a good therapy for Lyme disease are expected to boost the market growth in the future.
The Lyme disease treatment market is segmented into Administration Route, Treatment, and Distribution Channel.
Lyme disease is frequently misunderstood in people as a typical rash or a seasonal allergy because patients suffering from Lyme disease exhibit similar symptoms such as fever and body aching. This aspect is anticipated to hamper the expansion of the Lyme disease treatment market in the approaching years. Furthermore, a lack of public understanding regarding the frequency and symptoms of Lyme disease is expected to slow the market growth. Increased demand and frequency of Lyme disease throughout the world have led various companies to collaborate to develop vaccines for chronic Lyme disease. They are investing a large chunk of money to move on with their Lyme disease therapy initiative. For example, on July 19, 2021, Valneva SE, a vaccine company based in France, and Pfizer Inc, a pharmaceutical company based in the U.S., announced the completion of recruitment for the phase two trial of Lyme disease treatment vaccine candidate, VLA15-221. This aspect is expected to boost the growth of the Lyme disease market share.
The key players profiled in this report include GSK plc., Pfizer, Inc., Novartis AG, Mayne Pharma Group Limited, Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Inc., Orion Corporation, Perrigo Company plc., ChartwellPharma, and Almirall, LLC.
The global Lyme disease treatment market is segmented on the basis of treatment type, administration route, distribution channel, and region. By treatment type, the market is sub-segmented into medication and tick removal. By administration route, the market is classified into oral, injectable, and topical. By distribution channel, the market is classified into hospital pharmacies, retail pharmacies, and online. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
By treatment, the medication sub-segment dominated the market in 2021. The medicine sub-segment is expected to create significant income since healthcare providers prefer to administer drugs to patients so that their bodies can fight the illness and protect them from subsequent infections. Furthermore, ingesting medication is a more convenient choice than tick removal as it is a painless treatment option. As a result, such factors are projected to raise the popularity of Lyme disease treatment in the future. These are predicted to be the major factors affecting the Lyme disease treatment market size during the forecast period too.
By treatment, the tick removal second sub-segment is anticipated to show the fastest growth in 2031. There are several tick removal options for Lyme disease therapy. Some treatments may even injure the host by causing the tick to salivate and vomit into it. Ticks should be removed as soon as possible since the danger of disease transmission increases dramatically after 24 hours. The best outcomes are obtained by using blunt, medium-tipped, and angled forceps. Tick removal and the site of the tick bite should be thoroughly examined for any remaining mouthparts, which should be removed. After cleaning the area with an antiseptic solution, the patient is advised to keep an eye out for indications of local or systemic sickness. Antibiotic prophylaxis following tick removal is typically not recommended, however it may be explored in pregnant patients or in tick-borne illness endemic areas.
By administration route, the oral sub-segment dominated the global market share in 2021. The availability of products delivered orally is expected to drive the segment. Due to its efficacy against other tick-borne infections, physicians suggest doxycycline as the recommended medication for oral Lyme disease therapy. Such applications of Lyme disease treatment in the healthcare sector are bound to create a scope of growth for the sub-segment during the forecast period.
By distribution channel, the hospital pharmacies sub-segment dominated the market in 2021. The expansion of the sub-segment can be attributed to an increase in outpatient hospital visits and admissions by patients suffering from diseases such as chronic Lyme disease. Purchasing medication from hospital pharmacies is simple and handy for patients since they may obtain medications on time. Such variables are expected to boost market revenue even more. These are predicted to be the major factors affecting the Lyme disease treatment market size during the forecast period too.
By region, North America dominated the global Lyme disease treatment market in 2021 and is projected to remain the fastest-growing sub-segment during the forecast period. Lyme disease is a spirochete-caused multisystem infection. The most often reported vector-borne sickness in North America is borreliosis, which is caused by borrelia burgdorferi sensu stricto. 80% of the population in central and eastern Canada potentially were living in Lyme disease risk zones in 2020. Accurate identification and adequate therapy of tick-bitten individuals are important factors in reducing the effects of Lyme disease.
Impact of COVID-19 on the Global Lyme Disease Treatment Industry
- The prevalence of the COVID-19 pandemic slowed the rise of the Lyme disease market share. The epidemic of COVID-19 has had a negative impact on a variety of commercial sectors. Although the healthcare sector has had rapid expansion, particular illness areas, such as Lyme disease treatment, has encountered stiff competitive competition.
- Lyme disease and the COVID-19 sometimes begin with non-specific flu-like symptoms such as fever, headache, and general achiness and weariness, patients and medical authorities have become more worried about both infections in individuals. As a result, patients were advised to treat with the available oral drugs, which would aid in the diagnosis of other ailments.
- When treated quickly after the manifestation of symptoms, the National Institutes of Health activities in several areas of study for the treatment of Lyme disease show that most individuals recover within weeks after finishing a course of oral medications
Key Benefits For Stakeholders
- The report provides an exclusive and comprehensive analysis of the global Lyme disease market trends along with the Lyme disease treatment market forecast
- The report elucidates the lyme disease treatment market opportunity along with key drivers, and restraints of the market. It is a compilation of detailed information, inputs from industry participants and industry experts across the value chain, and quantitative and qualitative assessment by industry analysts.
- Porter’s five forces analysis helps analyze the potential of the buyers & suppliers and the competitive scenario of the lyme disease industry for strategy building
- The report entailing the lyme disease treatment market analysis maps the qualitative sway of various industry factors including the oral antibiotics industry and its impact on market segments as well as geographies
- The data in this report aims at market dynamics, trends, and developments affecting the Lyme disease treatment market growth
Lyme Disease Treatment Market Report Highlights
| Aspects | Details |
 By Administration Route |
|
 By Treatment |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Lupin Pharmaceuticals, Inc., Perrigo Company plc, Chartwell Pharmaceuticals, Pfizer, Inc., Mayne Pharma, Almirall, LLC, Orion Corporation, Galaxo SmithKline Plc, Novartis AG, Sun Pharmaceuticals Industries, Inc |
Analyst Review
Analyst Review: Global Lyme Disease Treatment Market
The Lyme disease treatment market is being driven by rising pet ownership and rising veterinary care spending. Furthermore, clinical research funded by government agencies and major firms to discover treatments for Lyme disease in humans and animals is propelling the Lyme disease therapy market forward. In addition, misdiagnosis of Lyme disease by healthcare professionals due to its comparable symptoms to other illnesses is expected to restrict the market expansion. However, increasing research to find effective medications for the treatment of Lyme disease is expected to create profitable opportunities for growing market throughout the forecast period. However, the lack of public understanding about the frequency and symptoms of Lyme disease is expected to stymie the market expansion.
Among the analyzed regions, North America is expected to account for the highest revenue in the market by the end of 2031, followed by Europe, Asia-Pacific, and LAMEA. Rapidly rising cases of Lyme disease among the people, worldwide are the key factors responsible for leading position of North America and Europe in the global Lyme disease treatment market.
Researchers are continuously trying to develop a potent vaccine for Lyme disease as the number of Lyme disease cases has increased. The rising number of cases and growing demand for a successful drug are likely to provide great scope for the growth of the global Lyme disease treatment market share. These are the upcoming trends in the market.
Lyme disease treatment market share is estimated to grow during the forecast period due to the rising incidence of Lyme disease among individuals worldwide. In addition, prolonged antibiotic use may wipe out beneficial intestinal flora, resulting in a variety of health concerns. This, in turn, is predicted to pose a threat to the growth of the Lyme disease treatment market.
North America is the largest regional market for Lyme disease treatment.
The Lyme disease treatment market is anticipated to reach $1,636.6 million by 2031.
GSK plc., Pfizer, Inc., Novartis AG, Mayne Pharma Group Limited, Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Inc., Orion Corporation, Perrigo Company plc., ChartwellPharma, and Almirall, LLC. are the major players in the Lyme disease treatment market.
Loading Table Of Content...
